Meridian Bioscience (Nasdaq: VIVO) reported earnings on Jan. 23. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Dec. 31 (Q1), Meridian Bioscience beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.

Margins expanded across the board.

Revenue details
 Meridian Bioscience chalked up revenue of $45.4 million. The eight analysts polled by S&P Capital IQ anticipated sales of $44.4 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $40.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.20. The 10 earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. GAAP EPS of $0.20 for Q1 were 25% higher than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 63.5%, 210 basis points better than the prior-year quarter. Operating margin was 28.9%, 340 basis points better than the prior-year quarter. Net margin was 18.7%, 240 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $48.7 million. On the bottom line, the average EPS estimate is $0.23.

Next year's average estimate for revenue is $189.4 million. The average EPS estimate is $0.87.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 475 rating the stock outperform, and 12 members rating it underperform. Among 118 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 115 give Meridian Bioscience a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $20.43.

Looking for alternatives to Meridian Bioscience? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.